第二军医大学学报  2021, Vol. 42 Issue (11): 1290-1295   PDF    
经前期烦躁障碍发病机制及治疗研究进展
李正1,2, 赵蕴晗1, 秦虹云1, 诸秉根1,2     
1. 同济大学附属精神卫生中心, 上海市浦东新区精神卫生中心, 上海 200124;
2. 同济大学医学院, 上海 200092
摘要: 经前期烦躁障碍(PMDD)在美国《精神障碍诊断和统计手册》第5版(DSM-5)中被列为心境障碍的一个类型,除了呈现情绪低落、烦躁等抑郁症状外,还可伴随躯体症状,具有经前期发作的特点。PMDD的病因和发病机制尚未明确,与其发病可能有关的因素包括雌性激素的波动、神经类固醇激素作用减弱、免疫激活和炎症反应、有关脑区(杏仁核、前额叶等)功能活动异常、心理社会因素等。因发病机制不明,PMDD尚未有根治性治疗方法,目前主要通过药物治疗(如抗抑郁药与口服避孕药)、心理治疗、中医药治疗(如中药、针灸)等方面缓解患者症状。
关键词: 经前期烦躁障碍    雌激素类    孕酮    抗抑郁药    口服避孕药    
Pathogenesis and treatment of premenstrual dysphoric disorder: research progress
LI Zheng1,2, ZHAO Yun-han1, QIN Hong-yun1, ZHU Bing-gen1,2     
1. Mental Health Center Affiliated to Tongji University, Shanghai Pudong New Area Mental Health Center, Shanghai 200124, China;
2. Tongji University School of Medicine, Shanghai 200092, China
Abstract: Premenstrual dysphoric disorder (PMDD) is diagnosed as a type of mood disorder in the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5). In addition to depressive symptoms, PMDD can be accompanied by somatic symptoms and is characterized by cyclicity (premenstrual). The etiology and pathogenesis of PMDD are not clear, probably involving the fluctuation of estrogen, the weakened role of neurosteroids hormones, immune activation and inflammatory response, the abnormal functional activities of some brain areas (such as amygdala, prefrontal cortex), psychosocial factors, etc. There is no radical treatment for PMDD due to the unknown pathogenesis. Treatments including drugs (such as antidepressants, oral contraceptives), psychotherapy, and complementary medicines (such as traditional Chinese medicine, acupuncture) are used to relieve patients' symptoms.
Key words: premenstrual dysphoric disorder    estrogens    progesterone    antidepressive agents    oral contraceptives    

经前期烦躁障碍(premenstrual dysphoric disorder,PMDD)是经前期综合征(premenstrual syndrome,PMS)的一个较为严重的类型,主要表现为女性在月经来潮前1周内周期性出现情感、行为和躯体症状,月经来潮后这些症状可自然缓解直至消失[1-3]。国外流行病学研究表明育龄期妇女PMS时点患病率为20%~30%,而其中较重的PMDD时点患病率约为1.2%~6.4%[1]。PMDD对患者生活质量有较大不良影响,目前尚没有根治性治疗方法,值得进一步从基础及临床多方面展开探索[1]

美国《精神障碍诊断和统计手册》第5版(Diagnostic and Statistical Manual of Mental Disorders 5th edition,DSM-5)将PMDD列为一种严重的心境(抑郁)障碍类型,并基于临床表现、病理生理和治疗方面的研究给出了较为全面的PMDD诊断方案。其核心诊断要点是月经前1周患者出现至少5种躯体、情感和/或行为症状,且至少要呈现1种关键性的不良情绪症状,如情绪波动、易哭泣、对于负性刺激的敏感性增强,易怒、人际冲突增多,显著的情绪低落、无望、自我否定感,或焦虑、紧张、易激动等[4-5]。PMDD患者的行为和躯体症状可表现为对日常活动兴趣减退、缺乏活力、食欲与睡眠改变,以及月经前特有的症状如乳房胀痛、小腹痛、身体肿胀感等,根据以上周期性症状表现及病史比较容易作出诊断。对月经周期进行必要的日常记录有助于清晰地将PMDD与其他精神疾患(如焦虑症、抑郁症等)区分开来,一般至少需要记录2个月经周期,常用的记录量表有每日严重情况记录(daily record of severity of problems,DRSP)[6]、每日症状等级(daily symptom rating,DSR)[7]、经前期每日体验记录(the calendar of premenstrual experiences,COPE)[8]等。

因发病机制不明,PMDD尚未有根治性治疗方法。本文对PMDD的发病机制及治疗方面的研究进展进行综述。

1 PMDD的发病机制

PMDD的病因和发病机制尚未明确,雌性激素的波动、神经类固醇激素作用减弱、免疫激活和炎症反应、有关脑区(杏仁核、前额叶等)功能活动异常、心理社会因素等多种因素均与PMDD的发病有关。

1.1 雌性激素

PMDD的发病机制尚不明确,因其症状随月经周期的特定时间出现和消失,提示雌性激素的波动是PMDD发病的重要机制。临床研究发现体内孕酮水平和用于避孕的类孕酮化合物(左炔诺孕酮、依托诺孕三醇、醋酸甲羟孕酮等)可能对PMDD患者的情绪产生影响[9]。孕酮水平在经期及卵泡期较低,其主要代谢产物四氢孕酮亦是一种神经活性类固醇激素。孕酮及四氢孕酮在黄体期时升高,经期则迅速降低。Smith等[10]认为这种卵巢激素的快速撤退可能是PMDD病因的关键所在。Li等[11]建立了孕酮撤退的大鼠模型,发现其表现出社交退缩和情感缺失的特性。临床前研究证实慢性的孕酮暴露伴随快速撤退与焦虑行为和γ-氨基丁酸(γ-aminobutyric acid,GABA)A受体功能变化相关[12],也有研究认为这种影响可能不是由孕酮本身而是由其主要代谢物四氢孕酮造成的[13]。四氢孕酮是GABAA受体有效的正性别构调节物。Nelson和Pinna[14]研究发现,在小鼠中产生的抑郁和焦虑样症状与四氢孕酮在杏仁核、海马和前额叶内侧的减少有关。此外,四氢孕酮对GABA的促进作用减弱,以及黄体期GABA A受体对神经活性类固醇激素敏感性不佳,可能也是PMDD的潜在病因机制[15]

雌二醇在情绪调控、认知、睡眠、饮食等多种由神经递质介导的行为中发挥作用[16]。PMDD患者在黄体期表现出情绪低落、对特定食物渴求及认知受损可能与5-羟色胺有关,这些患者体内的5-羟色胺可能对雌二醇的作用更为敏感。早期有关临床研究显示PMDD患者色氨酸缺失时,其经前症状加重[17];在黄体晚期雌二醇水平下降时,血液中5-羟色胺不足[18],由外源L-色氨酸生成5-羟色胺的反应变慢[19]。随后的临床研究及动物实验结果显示,雌二醇能改变5-羟色胺1a及2a受体[20-21]和5-羟色胺转运体的基因表达,从而影响情绪[22-23];雌二醇还可减少认知脑区单胺氧化酶A和儿茶酚邻位甲基转运酶的表达,提高脑源性神经营养因子(brain-derived neurotrophic factor,BDNF)的表达水平,进而影响认知能力[24]。有研究认为PMDD患者在出生前的胎儿期可能存在雌激素相对不足、雄激素水平相对偏高的情况,并且胎儿期2种激素的相对浓度与月经初潮后PMDD症状的严重程度有关[25]。此外,Huo等[26]研究发现雌二醇受体α基因的单核苷酸多态性与PMDD有关,且5-羟色胺1a基因多态性与5-羟色胺神经传递的减少和PMDD的主要抑郁症状有关。但PMDD病因复杂,且该研究样本量较小、不一定具有足够的代表性,基因多态性与PMDD的关系仍有待深入研究。

1.2 BDNF

BDNF在大脑多个区域表达,与学习、记忆和情感管理有关。BDNF可以被作用于5-羟色胺的抗抑郁药上调,受雌二醇的影响在月经周期中表现出周期性。Oral等[27]研究发现PMDD患者的黄体期血清BDNF含量高于正常对照组,且PMDD组内BDNF血清含量在黄体期高于卵泡期,提示黄体期BDNF代偿性增高,其产生的神经调制作用可能使患者在随后的卵泡期不表现出明显的PMDD相关抑郁症状。然而Cubeddu等[28]在PMS患者中的研究结果却有所不同,该研究结果显示PMS患者黄体期BDNF水平较卵泡期显著下降,而正常对照组黄体期BDNF水平显著高于卵泡期,并且PMS患者黄体期BDNF水平显著低于正常对照组黄体期BDNF水平,因此,作者认为PMS患者黄体期BDNF水平降低可能是激素反应改变的结果,这一机制可能在PMS发病过程中起作用。BDNF在PMS及PMDD中的确切作用及相关机制有待进一步研究证实。

1.3 早期创伤及应激压力

PMDD可能与早期创伤及当前应激压力相关。一项代表性的研究在对近4 000名女性调查后发现,早期创伤史与PMDD的诊断有关[29]。Bertone-Johnson等[30]在对1 018例14岁以上PMS患者和2 277名经历轻微月经症状的女性进行纵向对照研究后发现,情感(如长期故意冷落)和躯体虐待与严重的PMS息息相关,然而性虐待与PMS的关系并不明显。Segebladh等[31]的研究也显示PMDD患者并未比正常人遭受更高概率的躯体虐待、情感虐待和性虐待。总之,早期创伤和压力暴露史(如不良童年经历)可能使一些女性更容易受到月经周期激素波动的影响。四氢孕酮可能是压力暴露史导致PMDD的一个潜在机制,其在急性应激下水平增高,而在反复或慢性应激下该反应减弱;此外,早期创伤可能导致下丘脑-垂体-肾上腺轴和下丘脑-垂体-性腺轴的失调及卵巢类固醇激素对其的调节功能失调[32]

1.4 免疫反应和炎症

免疫系统参与情绪的调节,免疫功能和炎症反应失调与抑郁症的发生息息相关[33]。慢性炎症反应在PMDD的发病机制中可能也发挥重要作用。Bertone-Johnson等[34]对277名18~30岁女性进行横断面研究,结果显示调整年龄、吸烟状况和BMI后,月经症状总分与IL-2、IL-4、IL-10和IL-12水平呈正相关,情感性月经症状评分与IL-2水平呈线性相关,而身体/行为症状评分与IL-4和IL-12水平呈线性相关;此外,患有PMS的女性IL-4、IL-10、IL-12和γ干扰素水平均高于对照女性。Yama等[35]研究发现患有中重度PMS的女性患者月经前IL-10水平较对照组明显升高,并且月经后IL-10水平与抑郁症状评分呈正相关,表明IL-10可能与PMS有关。

1.5 脑区功能异常

神经影像学可评估大脑在月经周期中由激素介导的变化,作为PMDD的神经标志物,为了解PMDD的潜在病理生理机制提供有价值的信息。在功能影像学研究中,PMDD患者脑区多数指向杏仁核及前额叶等脑区[2]。功能磁共振成像结果显示,患有PMDD的女性与健康对照组相比在黄体后期杏仁核血氧水平依赖性(blood oxygenation level dependent,BOLD)信号升高(即PMDD患者杏仁核的激活水平更高),并且杏仁核反应性的变化与孕酮水平有关;此外,在黄体期晚期时,PMDD患者前扣带回皮质与杏仁核和岛叶之间的功能连通性较高[36]

1.6 中医病因病机观点

中医理论认为经前疾病由个人体质决定,肝、脾、肾功能失调及气血失和是月经前后诸证的重要因素。经行情志异常,以《内经》“五神脏”的观点来分析,情志病变首犯于心,心主神明、精神,是人体精神心理活动的主要调节者。如心有病变,就会影响到神志。当经前阴血下注,五脏失于濡养,心首当其冲。心动则五脏六腑皆摇,导致体重烦冤、悲、不乐、忧等经前焦虑障碍的表现[37]

2 PMDD的治疗

由于PMDD的病因和发病机制尚未明确,因此还没有从根本上解决患者病情的治疗问题。目前其治疗目的主要在于缓解患者情绪行为及躯体症状[1-3, 9],常用的方法包括抗抑郁药物、抑制排卵药物(激素)、心理行为治疗,以及一些传统疗法(如瑜伽、针灸等)。

2.1 抗抑郁药

选择性5-羟色胺重摄取抑制剂(selective serotonin reuptake inhibitor,SSRI)是PMDD和出现较重情绪问题的PMS患者的金标准治疗药物,每天口服20 mg氟西汀的症状缓解率达65%~75%[38-39]。此外对于较重患者也有学者尝试采用5-羟色胺和去甲肾上腺素重摄取抑制剂(serotonin-norepinephrine reuptake inhibitor,SNRI)及抗精神病药物(如喹硫平)治疗[3]。SSRI药物对PMDD治疗见效较快,在数小时至数天即可生效[40]。这种短期作用可以使患者间歇用药,即只在黄体期服药治疗,从排卵到月经来潮间使用。但是间歇给药只对易怒、情绪波动有效[41],抑郁情绪和较重的躯体症状则需不间断长期服用SSRI才能得到改善。常用的药物有氟西汀、西酞普兰、帕罗西汀和舍曲林,一般低剂量即可,因此不良反应较轻,对于初期的胃肠刺激症状患者一般都能耐受适应[42]

2.2 激素类药物

关于激素治疗PMDD的相关临床证据还比较有限。Lopez等[43]通过meta分析比较了联合口服包括合成孕激素屈螺酮在内的避孕药与安慰剂或其他联合口服避孕药对经前症状的影响,结果发现,3 mg屈螺酮加20 μg乙炔雌二醇可部分减轻严重的PMDD症状,但存在安慰剂效应。激素单一疗法可能没有激素联合使用有效,Ford等[44]的meta分析未发现单独使用孕酮有效的证据。对于一线治疗(如SSRI抗抑郁药、口服避孕药)效果不佳的症状严重患者,可以尝试使用促性腺激素释放激素(gonadotrophin-releasing hormone,GnRH)激动剂暂时终止月经周期[1]

2.3 其他疗法

Kleinstäuber等[45]的meta分析发现,除了SSRI类药物对治疗PMDD的焦虑症状有效外,认知-行为治疗(cognitive-behavior therapy,CBT)对减缓经前期症状也是有一定贡献的。Hunter等[46]比较了CBT(10个疗程)、氟西汀(20 mg/d)和两者联合疗法对PMDD患者的治疗效果,结果显示治疗6个月后CBT组与氟西汀组在疗效上基本相当,氟西汀起效快、对于焦虑症状有更大的改善,CBT能够提高患者对症状的认知水平、在随访期间更好地维持治疗效果,而两者联合使用并未表现出协同效果。近期有澳大利亚学者报道,夫妻共同参与的CBT比仅仅针对患者的CBT效果更好[47]

我国传统医学多以调畅气机兼补益调节诸脏气血的药物治疗PMDD,如柴胡、逍遥散等。随着对PMS和PMDD认识的提高,中医药治疗PMS和PMDD的临床研究也在不断增加,并取得了良好的效果[48]。除中药外,针灸和推拿也可改善PMS患者的生理和心理症状[49]。此外,瑜伽、有氧运动、膳食补充(钙质)也有利于改善女性的经前症状[3]

3 小结

近期国际上将PMDD归为心境障碍的一个类型,对于PMDD已经进行了多方面的研究,但其病因和发病机制仍然未有定论,可能涉及神经内分泌(包括有关递质)、免疫活化、有关脑区(如杏仁核、前额叶)功能活动异常与社会心理因素等多个方面。在治疗方面,目前主要采取抗抑郁药物、抑制排卵的激素、心理行为及传统疗法来缓解PMDD患者情绪行为和躯体症状。今后仍需进一步深入探讨PMDD的病因和发病机制,针对发病机制开发有针对性的治疗药物和干预策略,以提高患者生活质量。

参考文献
[1]
YONKERS K A, SIMONI M K. Premenstrual disorders[J]. Am J Obstet Gynecol, 2018, 218: 68-74. DOI:10.1016/j.ajog.2017.05.045
[2]
HANTSOO L, EPPERSON C N. Premenstrual dysphoric disorder: epidemiology and treatment[J/OL]. Curr Psychiatry Rep, 2015, 17: 87. DOI: 10.1007/s11920-015-0628-3.
[3]
HOFMEISTER S, BODDEN S. Premenstrual syndrome and premenstrual dysphoric disorder[J]. Am Fam Physician, 2016, 94: 236-240.
[4]
EISENLOHR-MOUL T A, GIRDLER S S, SCHMALENBERGER K M, DAWSON D N, SURANA P, JOHNSON J L, et al. Toward the reliable diagnosis of DSM-5 premenstrual dysphoric disorder: the Carolina premenstrual assessment scoring system (C-PASS)[J]. Am J Psychiatry, 2017, 174: 51-59. DOI:10.1176/appi.ajp.2016.15121510
[5]
American Psychiatric Association. Diagnostic and statistical manual of mental disorders[M]. 5th ed. Arlington: American Psychiatric Publishing, 2013: 165-168.
[6]
WU L, HE Z, ZHAO H, MA D, ZHANG S, DENG H, et al. Chinese version of Daily Record of Severity of Problems: reliability and validity[J]. J Adv Nurs, 2013, 69: 449-456. DOI:10.1111/j.1365-2648.2012.06070.x
[7]
BOSMAN R C, JUNG S E, MILOSERDOV K, SCHOEVERS R A, AAN HET ROT M. Daily symptom ratings for studying premenstrual dysphoric disorder: a review[J]. J Affect Disord, 2016, 189: 43-53. DOI:10.1016/j.jad.2015.08.063
[8]
KROLL-DESROSIERS A R, RONNENBERG A G, ZAGARINS S E, HOUGHTON S C, TAKASHIMA-UEBELHOER B B, BERTONE-JOHNSON E R. Recreational physical activity and premenstrual syndrome in young adult women: a cross-sectional study[J/OL]. PLoS One, 2017, 12: e0169728. DOI: 10.1371/journal.pone.0169728.
[9]
RAPKIN A J, KOROTKAYA Y, TAYLOR K C. Contraception counseling for women with premenstrual dysphoric disorder (PMDD): current perspectives[J]. Open Access J Contracept, 2019, 10: 27-39. DOI:10.2147/OAJC.S183193
[10]
SMITH S S, RUDERMAN Y, FRYE C, HOMANICS G, YUAN M. Steroid withdrawal in the mouse results in anxiogenic effects of 3α, 5β-THP: a possible model of premenstrual dysphoric disorder[J]. Psychopharmacology (Berl), 2006, 186: 323-333. DOI:10.1007/s00213-005-0168-3
[11]
LI Y, PEHRSON A L, BUDAC D P, SÁNCHEZ C, GULINELLO M. A rodent model of premenstrual dysphoria: progesterone withdrawal induces depression-like behavior that is differentially sensitive to classes of antidepressants[J]. Behav Brain Res, 2012, 234: 238-247. DOI:10.1016/j.bbr.2012.06.034
[12]
BIXO M, EKBERG K, POROMAA I S, HIRSCHBERG A L, JONASSON A F, ANDRÉEN L, et al. Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)-a randomized controlled trial[J]. Psychoneuroendocrinology, 2017, 80: 46-55. DOI:10.1016/j.psyneuen.2017.02.031
[13]
BÄCKSTRÖM T, HAAGE D, LÖFGREN M, JOHANSSON I M, STRÖMBERG J, NYBERG S, et al. Paradoxical effects of GABA-A modulators may explain sex steroid induced negative mood symptoms in some persons[J]. Neuroscience, 2011, 191: 46-54. DOI:10.1016/j.neuroscience.2011.03.061
[14]
NELSON M, PINNA G. S-norfluoxetine microinfused into the basolateral amygdala increases allopregnanolone levels and reduces aggression in socially isolated mice[J]. Neuropharmacology, 2011, 60: 1154-1159. DOI:10.1016/j.neuropharm.2010.10.011
[15]
UPPARI N P, JOSEPH V, BAIRAM A. Respiratory responses to progesterone and allopregnanolone following chronic caffeine treatment in newborn female rats[J]. Respir Physiol Neurobiol, 2017, 240: 32-40. DOI:10.1016/j.resp.2017.01.017
[16]
SHANMUGAN S, EPPERSON C N. Estrogen and the prefrontal cortex: towards a new understanding of estrogen's effects on executive functions in the menopause transition[J]. Hum Brain Mapp, 2014, 35: 847-865. DOI:10.1002/hbm.22218
[17]
MENKES D B, COATES D C, FAWCETT J P. Acute tryptophan depletion aggravates premenstrual syndrome[J]. J Affect Disord, 1994, 32: 37-44. DOI:10.1016/0165-0327(94)90059-0
[18]
RAPKIN A J, EDELMUTH E, CHANG L C, READING A E, MCGUIRE M T, SU T P. Whole-blood serotonin in premenstrual syndrome[J]. Obstet Gynecol, 1987, 70: 533-537.
[19]
RASGON N, MCGUIRE M, TANAVOLI S, FAIRBANKS L, RAPKIN A. Neuroendocrine response to an intravenous L-tryptophan challenge in women with premenstrual syndrome[J]. Fertil Steril, 2000, 73: 144-149. DOI:10.1016/S0015-0282(99)00452-5
[20]
KUGAYA A, EPPERSON C N, ZOGHBI S, VAN DYCK C H, HOU Y, FUJITA M, et al. Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women[J]. Am J Psychiatry, 2003, 160: 1522-1524. DOI:10.1176/appi.ajp.160.8.1522
[21]
HENDERSON J A, BETHEA C L. Differential effects of ovarian steroids and raloxifene on serotonin 1A and 2C receptor protein expression in macaques[J]. Endocrine, 2008, 33: 285-293. DOI:10.1007/s12020-008-9087-5
[22]
FINK G, SUMNER B E, MCQUEEN J K, WILSON H, ROSIE R. Sex steroid control of mood, mental state and memory[J]. Clin Exp Pharmacol Physiol, 1998, 25: 764-775. DOI:10.1111/j.1440-1681.1998.tb02151.x
[23]
CHAROENPHANDHU J, TEERAPORNPUNTAKIT J, NUNTAPORNSAK A, KRISHNAMRA N, CHAROENPHANDHU N. Anxiety-like behaviors and expression of SERT and TPH in the dorsal raphé of estrogen-and fluoxetine-treated ovariectomized rats[J]. Pharmacol Biochem Behav, 2011, 98: 503-510. DOI:10.1016/j.pbb.2011.02.023
[24]
BIMONTE-NELSON H A, NELSON M E, GRANHOLM A C E. Progesterone counteracts estrogen-induced increases in neurotrophins in the aged female rat brain[J]. Neuroreport, 2004, 15: 2659-2663. DOI:10.1097/00001756-200412030-00021
[25]
KANEOKE Y, DONISHI T, IWAHARA A, SHIMOKAWA T. Severity of premenstrual symptoms predicted by second to fourth digit ratio[J/OL]. Front Med (Lausanne), 2017, 4: 144. DOI: 10.3389/fmed.2017.00144.
[26]
HUO L, STRAUB R E, ROCA C, SCHMIDT P J, SHI K, VAKKALANKA R, et al. Risk for premenstrual dysphoric disorder is associated with genetic variation in ESR1, the estrogen receptor alpha gene[J]. Biol Psychiatry, 2007, 62: 925-933. DOI:10.1016/j.biopsych.2006.12.019
[27]
ORAL E, KIRKAN T S, YILDIRIM A, KOTAN Z, CANSEVER Z, OZCAN H, et al. Serum brain-derived neurotrophic factor differences between the luteal and follicular phases in premenstrual dysphoric disorder[J]. Gen Hosp Psychiatry, 2015, 37: 266-272. DOI:10.1016/j.genhosppsych.2015.03.001
[28]
CUBEDDU A, BUCCI F, GIANNINI A, RUSSO M, DAINO D, RUSSO N, et al. Brain-derived neurotrophic factor plasma variation during the different phases of the menstrual cycle in women with premenstrual syndrome[J]. Psychoneuroendocrinology, 2011, 36: 523-530. DOI:10.1016/j.psyneuen.2010.08.006
[29]
PILVER C E, LEVY B R, LIBBY D J, DESAI R A. Posttraumatic stress disorder and trauma characteristics are correlates of premenstrual dysphoric disorder[J]. Arch Womens Ment Health, 2011, 14: 383-393. DOI:10.1007/s00737-011-0232-4
[30]
BERTONE-JOHNSON E R, WHITCOMB B W, MISSMER S A, MANSON J E, HANKINSON S E, RICH-EDWARDS J W. Early life emotional, physical, and sexual abuse and the development of premenstrual syndrome: a longitudinal study[J]. J Womens Health (Larchmt), 2014, 23: 729-739. DOI:10.1089/jwh.2013.4674
[31]
SEGEBLADH B, BANNBERS E, KASK K, NYBERG S, BIXO M, HEIMER G, et al. Prevalence of violence exposure in women with premenstrual dysphoric disorder in comparison with other gynecological patients and asymptomatic controls[J]. Acta Obstet Gynecol Scand, 2011, 90: 746-752. DOI:10.1111/j.1600-0412.2011.01151.x
[32]
HANTSOO L, EPPERSON C N. Allopregnanolone in premenstrual dysphoric disorder (PMDD): evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle[J/OL]. Neurobiol Stress, 2020, 12: 100213. DOI: 10.1016/j.ynstr.2020.100213.
[33]
BEUREL E, TOUPS M, NEMEROFF C B. The bidirectional relationship of depression and inflammation: double trouble[J]. Neuron, 2020, 107: 234-256. DOI:10.1016/j.neuron.2020.06.002
[34]
BERTONE-JOHNSON E R, RONNENBERG A G, HOUGHTON S C, NOBLES C, ZAGARINS S E, TAKASHIMA-UEBELHOER B B, et al. Association of inflammation markers with menstrual symptom severity and premenstrual syndrome in young women[J]. Hum Reprod, 2014, 29: 1987-1994. DOI:10.1093/humrep/deu170
[35]
YAMA K, ASARI Y, ONO A, MACHIDA M, MIURA J. Plasma interleukin-10 levels are altered in women with severe premenstrual syndrome: a preliminary study[J]. Womens Health Rep (New Rochelle), 2020, 1: 73-79.
[36]
DUBOL M, EPPERSON C N, LANZENBERGER R, SUNDSTRÖM-POROMAA I, COMASCO E. Neuroimaging premenstrual dysphoric disorder: a systematic and critical review[J/OL]. Front Neuroendocrinol, 2020, 57: 100838. DOI: 10.1016/j.yfrne.2020.100838.
[37]
姜心禅, 范为之. 从《内经》"五神脏"角度浅析心与经前焦虑性障碍的相关性[J]. 中国中医药现代远程教育, 2016, 14: 41-42.
[38]
LANZA DI SCALEA T, PEARLSTEIN T. Premenstrual dysphoric disorder[J]. Med Clin North Am, 2019, 103: 613-628. DOI:10.1016/j.mcna.2019.02.007
[39]
MARJORIBANKS J, BROWN J, O'BRIEN P M, WYATT K. Selective serotonin reuptake inhibitors for premenstrual syndrome[J/OL]. Cochrane Database Syst Rev, 2013: CD001396. DOI: 10.1002/14651858.CD001396.
[40]
STEINBERG E M, CARDOSO G M, MARTINEZ P E, RUBINOW D R, SCHMIDT P J. Rapid response to fluoxetine in women with premenstrual dysphoric disorder[J]. Depress Anxiety, 2012, 29: 531-540. DOI:10.1002/da.21959
[41]
LANDÉN M, NISSBRANDT H, ALLGULANDER C, SÖRVIK K, YSANDER C, ERIKSSON E. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder[J]. Neuropsychopharmacology, 2007, 32: 153-161. DOI:10.1038/sj.npp.1301216
[42]
YONKERS K A, KORNSTEIN S G, GUEORGUIEVA R, MERRY B, VAN STEENBURGH K, ALTEMUS M. Symptom-onset dosing of sertraline for the treatment of premenstrual dysphoric disorder: a randomized clinical trial[J]. JAMA Psychiatry, 2015, 72: 1037-1044. DOI:10.1001/jamapsychiatry.2015.1472
[43]
LOPEZ L M, KAPTEIN A, HELMERHORST F M. Oral contraceptives containing drospirenone for premenstrual syndrome[J/OL]. Cochrane Database Syst Rev, 2008(1): CD006586. DOI: 10.1002/14651858.CD006586.pub2.
[44]
FORD O, LETHABY A, ROBERTS H, MOL B W J. Progesterone for premenstrual syndrome[J/OL]. Cochrane Database Syst Rev, 2009(2): CD003415(2016-08-01)[2019-03-18]. https://www.aafp.org/afp/2016/0801/p236.html.
[45]
KLEINSTÄUBER M, WITTHÖFT M, HILLER W. Cognitive-behavioral and pharmacological interventions for premenstrual syndrome or premenstrual dysphoric disorder: a meta-analysis[J]. J Clin Psychol Med Settings, 2012, 19: 308-319. DOI:10.1007/s10880-012-9299-y
[46]
HUNTER M S, USSHER J M, BROWNE S J, CARISS M, JELLEY R, KATZ M. A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder[J]. J Psychosom Obstet Gynaecol, 2002, 23: 193-199. DOI:10.3109/01674820209074672
[47]
USSHER J M, PERZ J. Evaluation of the relative efficacy of a couple cognitive-behaviour therapy (CBT) for premenstrual disorders (PMDs), in comparison to one-to-one CBT and a wait list control: a randomized controlled trial[J/OL]. PLoS One, 2017, 12: e0175068. DOI: 10.1371/journal.pone.0175068.
[48]
GAO M, SUN H, SUN W, GAO D, QIAO M. Traditional Chinese medicine on treating premenstrual syndrome and premenstrual dysphoric disorder: a protocol for systematic review and meta-analysis[J/OL]. Medicine (Baltimore), 2020, 99: e22694. DOI: 10.1097/MD.0000000000022694.
[49]
ARMOUR M, EE C C, HAO J, WILSON T M, YAO S S, SMITH C A. Acupuncture and acupressure for premenstrual syndrome[J/OL]. Cochrane Database Syst Rev, 2018, 8: CD005290. DOI: 10.1002/14651858.CD005290.pub2.